Clinical trials: Prostatic Disease
Prostate Carcinoma
An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
The purpose of this study is to evaluate the induction of immune responses against CV9104 administered by conventional intradermal injection or with a needle-free intradermal injection device and to assess the safety and…
- Trial name
- NCT02140138
- Testing
- CV9104, needle free injection device (Tropis®)
- Where
- 3 sites in Germany
- Volunteers
- 35 people
- Sponsor
- CureVac
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia…
- Trial name
- NCT00743184
- Testing
- ozarelix
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Prostate, Carcinoma
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia in hormone-refractory (not responding to hormone…
- Trial name
- NCT00364455
- Testing
- Epoetin alfa
- Volunteers
- 56 people
- Sponsor
- Janssen-Ortho Inc., Canada
Prostate Cancer, Adenocarcinoma
A Long Term Safety Study With Atrasentan
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
- Trial name
- NCT00127478
- Testing
- Atrasentan
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- Abbott
Benign Prostatic Hyperplasia (BPH), Overactive Bladder
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.
- Trial name
- NCT04485585
- Testing
- BR9006-1, BR9006-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Urology, Urinary Bladder, Overactive
Ambulatory Long Length URodynamics Evaluation
A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.
- Conditions
- Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics
- Trial name
- ALLURE (NCT07425015)
- Testing
- Glean Urodynamics System
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Bright Uro
Prostate Cancer
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
The primary objective of this study is: To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: To…
- Trial name
- NCT00273338
- Testing
- calcitriol, docetaxel
- Where
- 222 sites in United States, Canada and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Novacea
Prostatic Neoplasms
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.
- Trial name
- NCT07104110
- Testing
- QLH12016, abiraterone acetate, enzalutamide
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumors
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
- Trial name
- WEE1 (NCT04768868)
- Testing
- IMP7068
- Where
- 16 sites in United States, China and 1 more
- Volunteers
- 350 people
- Sponsor
- Impact Therapeutics, Inc.
Prostate Cancer
Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy
This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire
- Trial name
- AZTEK EXT (NCT00692874)
- Where
- 20 sites in Hungary
- Volunteers
- 1,646 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
- Trial name
- STRIKE-001 (NCT07103018)
- Testing
- KTX-2001, KTX-2001 + Darolutamide (NUBEQA®)
- Where
- 13 sites in United States
- Volunteers
- 144 people
- Sponsor
- K36 Therapeutics, Inc.
Metastatic Hormone-Sensitive Prostate Cancer
Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making.
- Trial name
- NCT06452212
- Testing
- No Intervention
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Korea, Inc.
Prostate Cancer
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand…
- Trial name
- NCT04186819
- Testing
- rhPSMA-7.3 (18F) Injection, Positron Emission Tomography scan
- Where
- 34 sites in United States, Finland and 2 more
- Volunteers
- 356 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
PCMRI - an MRI/TRUS System for the Evaluation of the Prostate
The aim of the clinical study is to evaluate the convenience and efficacy of the PCMRI in the assessment of the prostate in humans.
- Trial name
- PCMRI (NCT00542100)
- Testing
- PCMRI
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- TopSpin Medical
Prostatic Hyperplasia
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and…
- Trial name
- NCT01323998
- Testing
- 5ARI, AB
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Prostate Cancer
Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery
The study involves use of a device called an endomicroscope to obtain high resolution images of microscopic structures during robot-assisted prostate cancer surgery.
- Trial name
- NCT00792961
- Testing
- Endomicroscopy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Peter Delaney
Prostatic Neoplasms
PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone
To evaluate the overall tumor response rate in subjects with metastatic hormone refractory prostate cancer To evaluate PSA (tumor marker) response rate To evaluate safety
- Trial name
- NCT00291005
- Testing
- ARD6562, Docetaxel
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Sanofi
Prostatitis
An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland
The purpose of this study is to evaluate the safety and effectiveness of ELMIRON® in the treatment of chronic non-bacterial inflammation of the prostate gland.
- Trial name
- NCT00236990
- Testing
- pentosan polysulfate sodium
- Volunteers
- 283 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Prostate Cancer
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 5 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Trial name
- NCT07542379
- Testing
- 177Lu-FC516
- Where
- China
- Volunteers
- 13 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.